Thermogenesis Holdings Inc
NASDAQ:THMO
Intrinsic Value
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. [ Read More ]
The intrinsic value of one
THMO
stock under the Base Case scenario is
21.24
USD.
Compared to the current market price of 0.65 USD,
Thermogenesis Holdings Inc
is
Undervalued by 97%.
Thermogenesis Holdings Inc's market capitalization is 2m USD.
THMO stock price is 0.65 USD.
THMO stock price (0.65 USD) is 97% less than its Intrinsic Value (21.24 USD).
THMO has upside potential of 669% compared to the average analyst price target.
Open Wall St Estimates
THMO's Revenue has been growing by 1% per year for the last 3 years.
THMO's Revenue has dropped by 5% over the past 12 months.
THMO's long-term assets (16m USD) exceed its long-term liabilties (11m USD).
THMO has positive Gross Profit for the last twelve months.
THMO's short-term liabilties (9m USD) exceed its short-term assets (7m USD).
THMO's Revenue is forecast to grow at a rate of 27% per year over the next 3 years.
THMO's ROE (Return on Equity) has significantly decreased in the last 3 years from -193% to -297%, and is approaching profitability.
THMO's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -83% to -44%, and is approaching profitability.
THMO has negative Operating Income for the last twelve months.
THMO has negative Net Income for the last twelve months.
THMO's ROE (Return on Equity) for the past 12 months is negative and is equal to -297%.
THMO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -44%.
THMO has negative Free Cash Flow for the last twelve months.
THMO has negative three-year average ROE (Return on Equity): -276%. The company is not efficient at transforming stockholders' equity into net income.
THMO has negative three-year average ROIC (Return on Invested Capital): -58%. The company is not efficient at using invested capital to generate operating income.
THMO's D/E (Debt to Equity) is very low and is equal to 0.
THMO's Altman Z-Score is very low and is equal to -25.2.
THMO doesn't generate enough operating income (-6m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
Thermogenesis Holdings Inc
Balance Sheet Decomposition
Thermogenesis Holdings Inc
| Current Assets | 6.9m |
| Cash & Short-Term Investments | 4m |
| Receivables | 370k |
| Other Current Assets | 2.5m |
| Non-Current Assets | 9m |
| PP&E | 5.9m |
| Intangibles | 2m |
| Other Non-Current Assets | 1m |
| Current Liabilities | 8.9m |
| Accounts Payable | 590k |
| Accrued Liabilities | 1.2m |
| Other Current Liabilities | 7.1m |
| Non-Current Liabilities | 2.4m |
| Other Non-Current Liabilities | 2.4m |
Earnings Waterfall
Thermogenesis Holdings Inc
|
Revenue
|
9.7m
USD
|
|
Cost of Revenue
|
-7.3m
USD
|
|
Gross Profit
|
2.4m
USD
|
|
Operating Expenses
|
-8.2m
USD
|
|
Operating Income
|
-5.9m
USD
|
|
Other Expenses
|
-8.6m
USD
|
|
Net Income
|
-14.4m
USD
|
Free Cash Flow Analysis
Thermogenesis Holdings Inc
THMO Profitability Score
Profitability Due Diligence
Thermogenesis Holdings Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Thermogenesis Holdings Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
THMO Solvency Score
Solvency Due Diligence
Thermogenesis Holdings Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Thermogenesis Holdings Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
THMO Price Targets Summary
Thermogenesis Holdings Inc
According to Wall Street analysts, the average 1-year price target for
THMO
is 5 USD
.
Ownership
THMO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
THMO Price
Thermogenesis Holdings Inc
| Average Annual Return | -33.24% |
| Standard Deviation of Annual Returns | 64.45% |
| Max Drawdown | -100% |
| Market Capitalization | 2m USD |
| Shares Outstanding | 3 136 500 |
| Percentage of Shares Shorted | 2.5% |
THMO News
Last Important Events
Thermogenesis Holdings Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Thermogenesis Holdings Inc
Company Profile
Thermogenesis Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 39 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for large scale cell manufacturing services. The company manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory useand CAR-TXpress Platform for clinical manufacturing.
You don't have any saved screeners yet
